Detalhe da pesquisa
1.
Deficits in neuronal architecture but not over-inhibition are main determinants of reduced neuronal network activity in a mouse model of overexpression of Dyrk1A.
Cereb Cortex
; 34(1)2024 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37997361
2.
Exploring the link between hedonic overeating and prefrontal cortex dysfunction in the Ts65Dn trisomic mouse model.
Cell Mol Life Sci
; 80(12): 370, 2023 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37989807
3.
Functional implications of hippocampal adult neurogenesis in intellectual disabilities.
Amino Acids
; 45(1): 113-31, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23604404
4.
Deficits in neuronal architecture but not over-inhibition are main determinants of reduced neuronal network activity in a mouse model of overexpression of Dyrk1A.
bioRxiv
; 2023 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36945607
5.
uPA deficiency exacerbates muscular dystrophy in MDX mice.
J Cell Biol
; 178(6): 1039-51, 2007 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-17785520
6.
Ethanol-Induced Changes in Brain of Transgenic Mice Overexpressing DYRK1A.
Mol Neurobiol
; 57(7): 3195-3205, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32504418
7.
Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice.
Neurobiol Dis
; 36(2): 312-9, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19660545
8.
Infralimbic Neurotrophin-3 Infusion Rescues Fear Extinction Impairment in a Mouse Model of Pathological Fear.
Neuropsychopharmacology
; 42(2): 462-472, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27534266
9.
Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
Mol Nutr Food Res
; 58(2): 278-88, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24039182
10.
Reduced Mid1 Expression and Delayed Neuromotor Development in daDREAM Transgenic Mice.
Front Mol Neurosci
; 5: 58, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22563308
11.
Insights from mouse models to understand neurodegeneration in Down syndrome.
CNS Neurol Disord Drug Targets
; 9(4): 429-38, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20522013
12.
Pitfalls and hopes in Down syndrome therapeutic approaches: in the search for evidence-based treatments.
Behav Genet
; 36(3): 454-68, 2006 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-16520905